Transimmunization and the evolution of extracorporeal photochemotherapy
- PMID: 12126204
- DOI: 10.1016/s1473-0502(02)00011-3
Transimmunization and the evolution of extracorporeal photochemotherapy
Abstract
We are now aware that extracorporeal photopheresis (ECP) - in which a patient's leukocytes are isolated, passed through an ultrathin clear plastic plate, and exposed to 8-methoxypsoralen (8-MOP) and ultraviolet A light prior to reinfusion - is a simple and efficient dendritic cell (DC) therapy and the first FDA approved selective immunotherapy for cancer. DCs, as the most effective antigen presenting cells (APCs), are central to many ongoing efforts to stimulate immune responses to cancer cells. Moreover, ECP has not only demonstrated efficacy in the treatment of a T cell malignancy--namely cutaneous T-cell lymphoma (CTCL)--but also in treatment of oligoclonal T-cell-mediated diseases such as graft-versus-host-disease (GVHD) and organ transplant rejection. Recent advances in the understanding of DC/T-cell interactions provide insight into how ECP-induced DCs (EI-DCs) can be utilized to stimulate specific T-cell (i.e. anti-tumor) responses, or down-regulate a pre-existing potent T-cell response. The mechanism of this apparent paradox of EI-DC functionality is likely dependent on several fundamental principles: (1) the status of existing in vivo T-cell reactions, (2) the temporal stage of EI-DC differentiation, and (3) the affinity of the available repertoire of T-cell receptors (TCRs) for the antigen(s) in question. Further investigation into DC/T-cell interactions will help to shape the future of ECP and the ability to optimize this therapy for the desired immune effect. To this end, we are developing and testing Transimmunization to replace conventional ECP.
Comment in
-
Transimmunization: the science catches up to the clinical success.Transfus Apher Sci. 2002 Jun;26(3):177-80. doi: 10.1016/s1473-0502(02)00010-1. Transfus Apher Sci. 2002. PMID: 12126203 No abstract available.
Similar articles
-
Transimmunization, a novel approach for tumor immunotherapy.Transfus Apher Sci. 2002 Jun;26(3):205-16. doi: 10.1016/s1473-0502(02)00014-9. Transfus Apher Sci. 2002. PMID: 12126207 Review.
-
Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization.Technol Cancer Res Treat. 2002 Feb;1(1):65-9. doi: 10.1177/153303460200100109. Technol Cancer Res Treat. 2002. PMID: 12614179 Review.
-
Mechanisms of action of extracorporeal photochemotherapy.Transfus Apher Sci. 2003 Aug;29(1):61-70. doi: 10.1016/S1473-0502(03)00103-4. Transfus Apher Sci. 2003. PMID: 12877896 Review.
-
American council on ECP (ACE): Why now?J Clin Apher. 2018 Aug;33(4):464-468. doi: 10.1002/jca.21627. Epub 2018 Mar 25. J Clin Apher. 2018. PMID: 29575114
-
Cutaneous T cell lymphoma: the helping hand of dendritic cells.Ann N Y Acad Sci. 2001 Sep;941:1-11. Ann N Y Acad Sci. 2001. PMID: 11594563 Review.
Cited by
-
The use of photodynamic therapy in medical practice.Front Oncol. 2024 May 8;14:1373263. doi: 10.3389/fonc.2024.1373263. eCollection 2024. Front Oncol. 2024. PMID: 38803535 Free PMC article. Review.
-
Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents.Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD009759. doi: 10.1002/14651858.CD009759.pub4. Cochrane Database Syst Rev. 2022. PMID: 36166494 Free PMC article. Review.
-
Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents.Cochrane Database Syst Rev. 2022 Jun 9;6(6):CD009898. doi: 10.1002/14651858.CD009898.pub4. Cochrane Database Syst Rev. 2022. PMID: 35679154 Free PMC article. Review.
-
X-Ray Psoralen Activated Cancer Therapy (X-PACT).PLoS One. 2016 Sep 1;11(9):e0162078. doi: 10.1371/journal.pone.0162078. eCollection 2016. PLoS One. 2016. PMID: 27583569 Free PMC article.
-
Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.Cochrane Database Syst Rev. 2015 Dec 15;2015(12):CD009898. doi: 10.1002/14651858.CD009898.pub3. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2022 Jun 9;6:CD009898. doi: 10.1002/14651858.CD009898.pub4. PMID: 26666581 Free PMC article. Updated. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous